• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Nuclear Medicine Communications >Excretion and whole-body retention of radium-223 dichloride administered for the treatment of bone metastases from castration resistant prostate cancer
【24h】

Excretion and whole-body retention of radium-223 dichloride administered for the treatment of bone metastases from castration resistant prostate cancer

机译：用于治疗抗阉割前列腺癌骨转移的镭-223二氯化钠的排泄和全身保留

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

ObjectiveThe aim of the study was to determine the fraction of administered activity that was excreted and retained by a small cohort of patients who each received treatment with radium-223 dichloride (Ra-223). Ra-223 is an -emitting radionuclide that has been approved for use in the treatment of bone metastases that are secondary to castration resistant prostate cancer.Patients and methodsSix patients received two weight-based administrations of Ra-223 6 weeks apart. Activity excreted in the urine and faeces during the first 48h following each treatment was assessed by direct counting of the excreta. During the same period the whole-body retention of Ra-223 was also determined using a single probe counting system. The results of the excreta counting and the whole-body counting were compared to determine whether whole-body counting was a suitable surrogate for assessing excretion. Further whole-body retention counts were made at around 3, 4, 7 and 42 days following treatment.ResultsPatterns of excretion and retention of Ra-223 varied significantly between patients, but were similar for each patient's pair of treatments. The cumulative maximum activity excreted in the initial 8-h period following the Ra-223 administration was 2.6% that increased to 39% at 48h. The median excreted activity at similar to 1 and 6 weeks after treatment was 70 and 86%, respectively. Skeletal retention of Ra-223 at 6 weeks ranged from 11 to 60% of the administered activity.
机译：该研究的目的是确定施用活性的一小部分，其通过亚克镭-223-二氯化钠（RA-223）治疗的小群体排泄和保留。 Ra-223是一种批准的放射性核素，已被批准用于治疗继发性抗阉割前列腺癌的骨转移.Patiant和方法患者接受了两种基于重量的RA-223的含量。通过直接计数排泄物在每次治疗后的前48小时内排出尿液和粪便中的活性。在同一时期，使用单一探针计数系统也测定RA-223的全身保留。比较ExcreTa计数和全身计数的结果，以确定全身计数是否是评估排泄的合适替代物。进一步的全身保留计数在治疗后约3,4,7和42天进行。患者之间的排泄和Ra-223的保留率显着多种多样，但对每位患者的治疗相似。在RA-223给药后初始8-H期间排出的累积最大活性为2.6％，在48h增加到39％。在治疗后1和6周类似的中位排泄活动分别为70％和86％。骨骼保留6周的RA-223的次数范围为11至60％的施用活性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号